Cogent Biosciences

Yahoo Finance • 11 days ago

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that on Se... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz

[Close up of buildings in Wall Street] Alphotographic Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story

Yahoo Finance • 3 months ago

Cogent Biosciences stock hits 52-week high at 12.66 USD

Cogent Biosciences Inc. stock has reached a new 52-week high, hitting a price of 12.66 USD. According to InvestingPro data, the stock has shown remarkable momentum with a 51.9% gain over the past six months and currently trades at 12.75 US... Full story

Yahoo Finance • 3 months ago

Citi raises Cogent stock price target to $22 on bezuclastinib potential

Investing.com - Citi has raised its price target on Cogent (NASDAQ:COGT) to $22.00 from $15.00 while maintaining a Buy rating, citing positive results from the company’s SUMMIT trial. The new target sits well within the analyst range of $9... Full story

Yahoo Finance • 3 months ago

Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 7, Jefferies increased its price target on Cogent Biosciences, Inc. (NASDAQ:COGT) from $23 to $28 and reiterated a “Buy... Full story

Yahoo Finance • 3 months ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing... Full story

Yahoo Finance • 3 months ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing... Full story

Yahoo Finance • 3 months ago

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has... Full story

Yahoo Finance • 3 months ago

Tesla, Circle Internet Surge Among Monday's Market Cap Stock Movers

Monday’s trading session is showcasing significant movements across various market cap categories. Mega-cap giants like Tesla Motors (NASDAQ:TSLA) and Palantir Technologies Inc (NASDAQ:PLTR) have experienced notable shifts, while large... Full story

Yahoo Finance • 3 months ago

Cogent surges as bezuclastinib meets key goal in phase 2 mastocytosis trial

[Financial bar graph on futuristic digital landscape with glowing data] AlexSecret Cogent Biosciences (NASDAQ:COGT [https://seekingalpha.com/symbol/COGT]) surged ~31% Monday after releasing positive mid-stage data on bezuclastinib, its ca... Full story

Yahoo Finance • 3 months ago

Cogent Biosciences stock surges after positive trial results

Investing.com -- Cogent Biosciences, Inc. (NASDAQ:COGT) stock surged 10% after announcing positive top-line results from its SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM). The company reporte... Full story

Yahoo Finance • 3 months ago

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establis... Full story

Yahoo Finance • 4 months ago

Piper Sandler maintains Cogent stock rating ahead of pivotal trial data

Piper Sandler reiterated its Overweight rating and $24.00 price target on Cogent Biosciences (NASDAQ:COGT) Monday as the company approaches a crucial data readout for its drug bezuclastinib. Currently trading at $7.03, the stock sits well... Full story

Yahoo Finance • 4 months ago

Cogent Secures Up To $400 Mln Debt Facility From SLR Capital For Growth Strategy

(RTTNews) - On Wednesday, Cogent Biosciences, Inc. (COGT), a biotechnology company, announced it has secured a debt financing facility of up to $400 million from credit funds managed by SLR Capital Partners, LLC. An initial $50 million wa... Full story

Yahoo Finance • 5 months ago

Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Cogent Biosciences, Inc. (NASDAQ:COGT) stands against other top small cap stocks to buy wit... Full story

Yahoo Finance • 6 months ago

Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Cogent Biosciences Inc. (NASDAQ:COGT) stands against other biotech penny stocks. Peter... Full story

Yahoo Finance • 7 months ago

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four precl... Full story

Yahoo Finance • 8 months ago

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming... Full story

Yahoo Finance • 2 years ago

15 Small-Cap Stocks with High Potential

In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story

Yahoo Finance • 2 years ago

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster... Full story